Global Phosphoproteomics of DYRK1A Inhibition in Glioblastoma Cells

ABSTRACT: Here we performed a detailed investigation to delineate the role of DYRK1A in glioblastoma, using both pharmacological and genetic tools combined with global phosphoproteomics. Our data show that DYRK1A inhibitors affect a much broader proportion of the phosphoproteome than DYRK1A knockdown. By overlaying these datasets we identify a pool of 61 putative novel DYRK1A targets, and validate CDC23 Ser588 as a bona-fide DYRK1A substrate. CDC23 is a ubiquitin ligase that degrades mitotic proteins, and DYRK1A inhibiton thereby leads to the accumulation of cyclin B and activation of CDK1.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Astrocyte

DISEASE(S): Glioblastoma

SUBMITTER: Sean Humphrey  

LAB HEAD: Sean Humphrey

PROVIDER: PXD020441 | Pride | 2021-04-22

REPOSITORIES: Pride